# Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities

> **NCT04167553** · PHASE1 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 52 (actual)

## Conditions studied

- Obese With Comorbidities
- Overweight With Comorbidities
- Type2 Diabetes

## Interventions

- **DRUG:** HM15136
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04167553
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-30
- **Primary completion:** 2020-12-09
- **Final completion:** 2020-12-09
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04167553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04167553, "Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04167553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*